Cargando...
Dynamics of Hepatitis B Virus Resistance to Lamivudine
Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who...
Gardado en:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Microbiology
2006
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1346832/ https://ncbi.nlm.nih.gov/pubmed/16378967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.80.2.643-653.2006 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|